J
Joseph B. Quinn
Researcher at Durham University
Publications - 26
Citations - 3814
Joseph B. Quinn is an academic researcher from Durham University. The author has contributed to research in topics: Lamivudine & Emtricitabine. The author has an hindex of 22, co-authored 26 publications receiving 3666 citations. Previous affiliations of Joseph B. Quinn include GlaxoSmithKline.
Papers
More filters
Journal ArticleDOI
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B
Patrick Marcellin,E. Jenny Heathcote,Maria Buti,Edward Gane,Robert A. de Man,Zahary Krastev,George Germanidis,Sam Lee,Robert Flisiak,Kelly Kaita,Michael P. Manns,Iskren Kotzev,Konstantin Tchernev,Peter Buggisch,Frank Weilert,Oya Ovung Kurdas,Mitchell L. Shiffman,Huy N. Trinh,Mary Kay Washington,Jeff Sorbel,Jane Anderson,Andrea Snow-Lampart,Elsa Mondou,Joseph B. Quinn,Franck Rousseau +24 more
TL;DR: Among patients with chronic HBV infection, tenofovir DF at a daily dose of 300 mg had superior antiviral efficacy with a similar safety profile as compared with adefovir dipivoxil at adaily dose of 10 mg through week 48.
Journal ArticleDOI
Treatment with Lamivudine, Zidovudine, or Both in HIV-Positive Patients with 200 to 500 CD4+ Cells per Cubic Millimeter
Joseph J. Eron,Sharon L. Benoit,Joseph Jemsek,Rodger D. MacArthur,Jorge Santana,Joseph B. Quinn,Daniel R. Kuritzkes,Mary Ann Fallon,Marc Rubin +8 more
TL;DR: In HIV-infected patients with little or no prior antiretroviral therapy, treatment with a combination of lamivudine and zidovudine is well tolerated over a one-year period and produces more improvement in immunologic and virologic measures than does treatment with either agent alone.
Journal ArticleDOI
Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults.
TL;DR: The results suggest that three drug regimens containing two NRTI with a PI, a NNRTI, or a third N RTI may provide comparable activity, and practical issues such as daily pill burden should be considered when choosing a treatment regimen.
Journal ArticleDOI
Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects.
Ian Sanne,Herve Mommeja-Marin,John Hinkle,John Bartlett,Michael M. Lederman,Gary Maartens,Charles Wakeford,Audrey L. Shaw,Joseph B. Quinn,Robert G. Gish,Franck Rousseau +10 more
TL;DR: The use of nevirapine in female patients with a low BMI should be discouraged and the occurrence of early hepatotoxicity was 17% in the ne virapine group and 0% inThe efavirenz group and was balanced between the lamivudine and emtricitabine arms.
Journal ArticleDOI
An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults.
John Bartlett,Michael J Fath,Ralph DeMasi,Ashwaq Hermes,Joseph B. Quinn,Elsa Mondou,Franck Rousseau +6 more
TL;DR: NNRTI and BPI-containing regimens offer superior virologic suppression over 48 weeks, supporting existing guidelines for the choice of initial ART and identifying the predictors of responses.